AKT1 and hearing loss disorder: Recent study reported that a low dose intraperitoneal injection of sirolimus (mTOR inhibitor) attenuated age-related hearing loss by decreasing the mTORC1, while high dose of sirolimus caused severe hearing loss by decreasing mTORC2/Akt.